Special Issue "The Molecular Pathology of Myelodysplastic Syndromes"

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 15 February 2023 | Viewed by 746

Special Issue Editor

Dr. Victor E. Nava
E-Mail Website
Guest Editor
1. Veterans Affairs Medical Center, Washington, DC 20422, USA
2. Department of Pathology, George Washington University, Washington, DC 20037, USA
Interests: pathology; hematopathology; molecular biology; virology; immunology; oncogenesis; parasitology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Myelodysplastic syndromes (MDS) comprise heterogeneous blood malignancies overlapping with myeloproliferative neoplasms, which can especially affect the elderly in the absence of genetic diseases. These disorders are defined by clonal stem cell defects, which affect proliferation, differentiation and apoptosis, resulting in chronic dysplastic cytopenias (ineffective hematopoiesis and even bone marrow aplasia) with or without myelofibrosis, frequently evolving into acute myeloid leukemia. Despite significant progress, including the discovery that approximately 90% of MDS harbor recurrent genetic alterations, these entities remain intractable and curable only with bone marrow transplantation, which is impossible in most cases due to advance age and associated co-morbidities.

This review series focuses on the molecular underpinnings of MDS using the framework of the upcoming World Health Organization classification update. Clinicopathological and molecular features are considered in relation to the diagnostic and therapeutic challenges posed by this rare disease. Accordingly, new analytic tools, including artificial intelligence of digitalized micrographs would be welcomed.

Dr. Victor E. Nava
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myelodysplastic syndrome
  • myeloproliferative neoplasm
  • molecular pathology
  • acute myeloid leukemia
  • next generation sequencing
  • personalized medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Case Report
Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation
Curr. Oncol. 2022, 29(7), 4587-4592; https://doi.org/10.3390/curroncol29070363 - 29 Jun 2022
Viewed by 657
Abstract
Myelodysplastic syndromes (MDS) and Waldenstrom’s macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development [...] Read more.
Myelodysplastic syndromes (MDS) and Waldenstrom’s macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with somatic mutation (L265P) of myeloid differentiation primary response 88 gene (MYD88) in 80–90%, or various mutations of C-terminal domain of the C-X-C chemokine receptor type 4 (CXCR4) gene in 20–40% of cases. A unique, progressive case of concurrent MDS and WM with several somatic mutations (some unreported before) and a novel balanced reciprocal translocation between chromosomes 10 and 13 is presented below. Full article
(This article belongs to the Special Issue The Molecular Pathology of Myelodysplastic Syndromes)
Show Figures

Figure 1

Back to TopTop